Test Compendium
Test Compendium is your definitive resource for detailed information on a wide array of diagnostic tests. Each entry in our compendium is meticulously cataloged to aid healthcare providers in selecting and interpreting the right tests for their patients.
Displaying 451 - 475 of 475
Concurrent DeepSight™ Comprehensive 523 genes Liquid Biopsy (Somatic) + Neovare Portfolio testing (Germline)
MolecularConcurrent DeepSight™ Comprehensive 523 genes Liquid Biopsy (Somatic) + Neovare Portfolio testing (Germline) Methodology Molecular Test Description Disease Solid tumors; Breast cancer, Ovarian cancer,
Concurrent DeepSight™ on Liquid + siPortfolio Multi-Omics™ on Tissue
MolecularConcurrent DeepSight™ on Liquid + siPortfolio Multi-Omics™ on Tissue Methodology Molecular Test Description Disease Solid tumorsOn Tissue: siPortfolio Multi-Omics™ • NGS (500+ genes, TMB, MSI)
LymphoSight™
LymphoSight™ Test Description Probes/Genes IHC/CISH ALK1, BCL-1, BCL-2, BCL-6, BRAF, Bob1, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD15, CD20, CD21, CD23, CD25*, CD30, CD43, CD79a, CD138, C-MYC, EBV-LMP, Granzyme B, ICOS*, IgA, IgG, IgG4, IgM, Kappa, Ki-67, Lambda, LEF1*, Mum1, OCT2, Pax5, Perforin, PD-1, TIA1. *: Pending CISH: EBER, Kappa,
Chronic Lymphocytic Leukemia (CLL) Flow Panel
Flow cytometryChronic Lymphocytic Leukemia (CLL) Flow Panel Methodology Flow cytometry Test Description Probes/Genes CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD16, CD19, CD20, CD23, CD38, CD43, CD45, CD49d, CD56,
Hairy Cell Leukemia (HCL) Flow Panel
Flow cytometryHairy Cell Leukemia (HCL) Flow Panel Methodology Flow cytometry Test Description Probes/Genes CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD16, CD19, CD20, CD23, CD25, CD38, CD45, CD56, CD57, CD103, CD123,
Diffuse Large B-Cell Lymphoma / Follicular Lymphoma Flow Panel
Flow cytometryDiffuse Large B-Cell Lymphoma / Follicular Lymphoma Flow Panel Methodology Flow cytometry Test Description Probes/Genes CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD16, CD19, CD20, CD23, CD25, CD38, CD45,
T-cell Lymphoproliferative Disorder Flow Panel
Flow cytometryT-cell Lymphoproliferative Disorder Flow Panel Methodology Flow cytometry Test Description Probes/Genes CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD16, CD19, CD20, CD23, CD25, CD26, CD30, CD38, CD45,
Myeloma Flow Panel
Flow cytometryMyeloma Flow Panel Methodology Flow cytometry Test Description Probes/Genes CD3, CD4, CD8, CD19, CD20, CD27, CD28, CD38, CD45, CD56, CD81, CD117, CD138, IgA, IgG, IgM, cKappa, cLambda Disease Anemia,
Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma Flow Panel
Flow cytometryWaldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma Flow Panel Methodology Flow cytometry Test Description Probes/Genes CD3, CD4, CD5, CD8, CD14, CD19, CD20, CD27, CD28, CD33, CD34, CD38, CD45, CD56,
Myeloma MRD Flow Panel
Flow cytometryMyeloma MRD Flow Panel Alternative Name Myeloma Measurable/Minimal Residual Disease Methodology Flow cytometry Test Description Probes/Genes CD19, CD27, CD45, CD56, CD81, CD117, CD138, cKappa, cLambda,
Paroxysmal nocturnal hemoglobinuria (PNH) - peripheral blood panel
Flow cytometryParoxysmal nocturnal hemoglobinuria (PNH) - peripheral blood panel Methodology Flow cytometry Test Description Probes/Genes CD14, CD15, CD24, CD45, CD64, FLAER Alexa-488, CD59, CD235a Disease Paroxysmal
Paroxysmal nocturnal hemoglobinuria (PNH) - bone marrow aspirate panel
Flow cytometryParoxysmal nocturnal hemoglobinuria (PNH) - bone marrow aspirate panel Methodology Flow cytometry Test Description Probes/Genes CD59, CD235a Disease Paroxysmal nocturnal hemoglobinuria (PNH)Paroxysmal
DeepSight™ Comprehensive Liquid Biopsy
MolecularDeepSight™ Comprehensive Liquid Biopsy Alternative Name Liquid Biopsy 523 Genes Panel Methodology Molecular Test Description Genes *ABL1, ABL2, ACVR1, ACVR1B, AKT1, AKT2
DeepSight™ Focused Liquid Biopsy
MolecularDeepSight™ Focused Liquid Biopsy Alternative Name Liquid Biopsy 50 Genes Panel Methodology Molecular Test Description Genes DNA HOTSPOT GENES (45) AKT1, AKT2, AKT3, ALK,
OncoSwift® 50 ? 500 Comprehensive Panel
MolecularOncoSwift® 50 ? 500 Comprehensive Panel Methodology Molecular Test Description Genes HOTSPOT GENES (57) ACVR1, ATP1A1, BCR, BMP5 BTK CACNA1D CD79B CSF1R CTNNB1 CUL1
Oncoswift® Frontier
Oncoswift® Frontier Test Description Probes/Genes DNA HOTSPOT GENES (44) AKT1, AKT2, ALK, AR, ARAF, BRAF, CDK4, CDKN2A, CHEK2 CTNNB1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR1, FGFR2,
Prosigna™Breast Cancer Prognostic Gene Signature Assay
MolecularProsigna™Breast Cancer Prognostic Gene Signature Assay Methodology Molecular Test Description Disease breast cancerThe Prosigna® Breast Cancer Prognostic Gene Signature Assay is an in vitro diagnostic
Expanded Hereditary 89-Gene Panel (Individual Genes)
MolecularExpanded Hereditary 89-Gene Panel (Individual Genes) Methodology Molecular Test Description Genes *AKT1, *ALK, APC, ASXL1, ATM, AXIN2, BAP1, BARD1, BLM, BRCA1, BRCA2, BRIP1 , *CASR , CDC73 , CDH1, *CDK4,
LymphoSight™
LymphoSight™ Test Description Probes/Genes IHC/CISH ALK1, BCL-1, BCL-2, BCL-6, BRAF, Bob1, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD15, CD20, CD21,
Concurrent DeepSight™ Comprehensive 523 genes Liquid Biopsy (Somatic) + Neovare Portfolio testing (Germline)
MolecularConcurrent DeepSight™ Comprehensive 523 genes Liquid Biopsy (Somatic) + Neovare Portfolio testing (Germline) Methodology Molecular Test Description Disease Solid tumors; Breast cancer, Ovarian cancer,
Concurrent DeepSight™ on Liquid + siPortfolio Multi-Omics™ on Tissue
MolecularConcurrent DeepSight™ on Liquid + siPortfolio Multi-Omics™ on Tissue Methodology Molecular Test Description Disease Solid tumorsOn Tissue: siPortfolio Multi-Omics™ • NGS (500+ genes, TMB, MSI) • HRD for
FOLR-1
Immunohistochemistry (IHC)FOLR-1 Alternative Name folate receptor alpha Methodology Immunohistochemistry (IHC) Test Description Disease epithelial ovarian cancer (EOC)FOLR1 (FOLR1-2.1) RxDx Assay is the first and only immunohistochemistry
PRAME
Immunohistochemistry (IHC)PRAME Alternative Name PReferentially expressed Antigen in MElanoma Methodology Immunohistochemistry (IHC) Test Description Disease Differential diagnoses of benign versus malignant melanocytic lesions,
HPV-HR
In Situ Hybridization (ISH)HPV-HR Alternative Name Human papillomavirus (HPV)- High Risk , HPV RNA ISH 16/18, HPV RNA ISH High Risk Cocktail Methodology In Situ Hybridization (ISH) Test Description Disease Types of HPV can cause
HPV-LR
In Situ Hybridization (ISH)HPV-LR Alternative Name Human papillomavirus (HPV)- Low Risk , HPV RNA ISH Low Risk Cocktail Methodology In Situ Hybridization (ISH) Test Description Disease Low risk, or non-oncogenic, types of the virus
PDL 28-8
Immunohistochemistry (IHC)PDL 28-8 Alternative Name PD-L1 28-8 (OPDIVO®) Methodology Immunohistochemistry (IHC) Test Description Disease Gastric/GEJ/Esophageal AdenocarcinomaPD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical
PDL SP263
Immunohistochemistry (IHC)PDL SP263 Alternative Name IMFINZI Methodology Immunohistochemistry (IHC) Test Description Disease non-small cell lung cancer (NSCLC)PD-L1 (SP263) assay is a qualitative immunohistochemical assay using
PDL SP142
Immunohistochemistry (IHC)PDL SP142 Alternative Name PD-L1 SP142 FDA (TECENTRIQ®) Methodology Immunohistochemistry (IHC) Test Description Disease non-small cell lung cancer (NSCLC)PD-L1 (SP142) Assay is a qualitative immunohistochemical
